Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.47% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CNST
1926
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $4.42M | ﹤0.01% |
+93,779
| New | +$2.71M |
|
|
SUNE
1927
SUNation Energy
SUNE
$8.95M
| $4.4M | ﹤0.01% |
1
| – | – |
|
|
PRNB
1928
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $4.4M | ﹤0.01% |
+80,400
| New | +$3M |
|
|
FRBK
1929
DELISTED
Republic First Bancorp Inc
FRBK
| $4.4M | ﹤0.01% |
1,053,233
+382,300
| +57% | +$1.55M |
|
1930
Spyre Therapeutics
SYRE
$8.54B
| $4.4M | ﹤0.01% |
23,036
+608
| +3% | +$119K |
|
|
ARAV
1931
DELISTED
Aravive, Inc. Common Stock
ARAV
| $4.39M | ﹤0.01% |
321,304
+148,645
| +86% | +$1.31M |
|
|
ACH
1932
DELISTED
Alum Corp of China Ltd
ACH
| $4.39M | ﹤0.01% |
505,281
-1,919
| -0.4% | -$15.3K |
|
1933
Nexa Resources
NEXA
$1.7B
| $4.39M | ﹤0.01% |
539,300
-10,800
| -2% | -$98.5K |
|
1934
Natural Alternatives International
NAII
$14.4M
| $4.39M | ﹤0.01% |
549,598
+10,615
| +2% | +$89.7K |
|
1935
Vince Holding Corp
VNCE
$81.3M
| $4.39M | ﹤0.01% |
253,352
+89,001
| +54% | +$1.86M |
|
|
CTO
1936
CTO Realty Growth
CTO
$824M
| $4.38M | ﹤0.01% |
267,753
+50,397
| +23% | +$870K |
|
|
BHR
1937
Braemar Hotels & Resorts
BHR
$156M
| $4.37M | ﹤0.01% |
489,509
-41,120
| -8% | -$385K |
|
1938
Protagonist Therapeutics
PTGX
$8.79B
| $4.36M | ﹤0.01% |
618,124
+63,024
| +11% | +$626K |
|
|
CPLG
1939
DELISTED
CorePoint Lodging Inc. Common Stock
CPLG
| $4.35M | ﹤0.01% |
407,424
-9,176
| -2% | -$92.6K |
|
1940
Syndax Pharmaceuticals
SNDX
$1.69B
| $4.35M | ﹤0.01% |
495,500
-1,500
| -0.3% | -$11K |
|
|
PMD
1941
DELISTED
Psychemedics Corporation
PMD
| $4.35M | ﹤0.01% |
475,177
+22,311
| +5% | +$206K |
|
1942
Distribution Solutions Group
DSGR
$1.6B
| $4.34M | ﹤0.01% |
166,654
+32,654
| +24% | +$772K |
|
1943
Compugen
CGEN
$222M
| $4.33M | ﹤0.01% |
727,000
+88,400
| +14% | +$455K |
|
1944
Toll Brothers
TOL
$13.6B
| $4.32M | ﹤0.01% |
+109,300
| New | +$4.37M |
|
|
OMCC
1945
DELISTED
Old Market Capital Corp
OMCC
| $4.32M | ﹤0.01% |
523,755
-6,426
| -1% | -$57.1K |
|
1946
State Street SPDR Nuveen ICE High Yield Municipal Bond ETF
HYMB
$3.09B
| $4.31M | ﹤0.01% |
146,100
-60,500
| -29% | -$1.79M |
|
|
TGB
1947
Trekor Metals
TGB
$2.48B
| $4.31M | ﹤0.01% |
8,979,157
+669,604
| +8% | +$283K |
|
1948
Red Rock Resorts
RRR
$3.77B
| $4.31M | ﹤0.01% |
179,800
+19,800
| +12% | +$440K |
|
|
TGA
1949
DELISTED
Transglobe Energy Corp
TGA
| $4.3M | ﹤0.01% |
3,116,913
+47,446
| +2% | +$59K |
|
1950
ICL Group
ICL
$6.53B
| $4.29M | ﹤0.01% |
895,675
+11,500
| +1% | +$53.1K |
|
Similar funds
Renaissance Technologies's Q4 2019 Portfolio in Review
As of Q4 2019, Renaissance Technologies held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Renaissance Technologies's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Renaissance Technologies's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Renaissance Technologies added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Renaissance Technologies's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Renaissance Technologies fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Renaissance Technologies's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Renaissance Technologies opened 518 new positions and closed 443 in Q4 2019.
- Renaissance Technologies's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.